Skip to main content

The Cigna Group (CI) Stock Analysis

Range Bound setup

SellModerate Confidence

Healthcare · Healthcare Plans

Sell if holding. Engine safety override at $290.49: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: Elevated put/call ratio: 1.62; Below-average business quality.

Cigna Group is a global health company with two segments: Evernorth Health Services (pharmacy benefit management via Express Scripts, specialty pharmacy Accredo, and care services) and Cigna Healthcare (employer and individual health insurance, international health). Serves... Read more

$290.49+5.1% A.UpsideScore 5.7/10#4 of 11 Healthcare Plans
QualityF-score7 / 9FCF yield8.99%
IncomeYield2.14%(5y avg 1.65%)Payout5.36%sustainable
Stop $276.38Target $306.45(analyst − 10%)A.R:R 0.8:1
Analyst target$340.50+17.2%24 analysts
$306.45our TP
$290.49price
$340.50mean
$378

Sell if holding. Engine safety override at $290.49: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: Elevated put/call ratio: 1.62; Below-average business quality. Chart setup: RSI 51 mid-range, Bollinger mid-band. Score 5.7/10, moderate confidence.

Passes 7/10 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 70d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.

Val8.3Qual3.9Grw5.8Mom5.3Sent6.4Ins3.8Peer6.0Tech4.7Risk5.95.7OVERALL

Recent Developments — The Cigna Group

Latest news

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Supplier: one pharmaceutical wholesaler (approximately half of pharmaceutical purchases)
Cyclical trap - fwd PE 9x vs trail 3x (3.4x)
Quality below floor (3.9 < 4.0)

Key Metrics

P/E (TTM)2.6
P/E (Fwd)8.7
Mkt Cap$77.1B
EV/EBITDA7.5
Profit Mgn2.3%
ROE16.3%
Rev Growth4.6%
Beta0.31
Dividend2.14%
Rating analysts34

Quality Signals

Piotroski F7/9

Options Flow

P/C1.62bearish
IV40%normal
Max Pain$195-32.9% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHSupplierone pharmaceutical wholesaler (approximately half of pharmaceutical purchases)
    10-K Item 1: 'Evernorth Health Services uses one wholesaler for approximately half of our pharmaceutical purchases, but holds contracts with other wholesalers if needs for an alternate source arise'

Material Events(8-K, last 90d)

  • 2026-03-03Item 5.02MEDIUM
    Brian C. Evanko appointed CEO effective July 1, 2026, succeeding David M. Cordani who retires as CEO and becomes Executive Chair. Clean handoff with named successor; Cordani stays on as Executive Chair.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Gross Margin
0.0
Net Margin
1.1
Operating Margin
2.2
Roa
3.2
Current Ratio
3.3
Moat
5.0
Roe
5.4
Fcf Quality
7.5
Piotroski F
7.8
No competitive moatStrong Piotroski F-Score: 7/9
GatesA.R:R 0.8 < 1.5@spotMomentum 5.3<5.5 (soft — BUY_NOW allowed but watch)Death cross (50MA < 200MA)Momentum 5.3>=4.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 70d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Moderate
RSI
51 · Neutral
↑ 20D MA↑ 50D MA↑ 200D MADEATH CROSSSupport $272.33Resistance $303.33

Price Targets

$276
$306
A.Upside+5.5%
A.R:R0.8:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Cyclical trap - fwd PE 9x vs trail 3x (3.4x)
! Quality below floor (3.9 < 4.0)
! Reward/Risk 0.8:1 at current price — below 1.5:1 minimum

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-07-30 (70d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is CI stock a buy right now?

Sell if holding. Engine safety override at $290.49: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: Elevated put/call ratio: 1.62; Below-average business quality. Chart setup: RSI 51 mid-range, Bollinger mid-band. Prior stop was $276.38. Score 5.7/10, moderate confidence.

What is the CI stock price target?

Take-profit target: $306.45 (+5.1% upside). Prior stop was $276.38. Stop-loss: $276.38.

What are the risks of investing in CI?

Concentration risk — Supplier: one pharmaceutical wholesaler (approximately half of pharmaceutical purchases); Cyclical trap - fwd PE 9x vs trail 3x (3.4x); Quality below floor (3.9 < 4.0).

Is CI overvalued or undervalued?

The Cigna Group trades at a P/E of 2.6 (forward 8.7). TrendMatrix value score: 8.3/10. Verdict: Sell.

What do analysts say about CI?

34 analysts cover CI with a consensus score of 4.2/5. Average price target: $341.

What does The Cigna Group do?Cigna Group is a global health company with two segments: Evernorth Health Services (pharmacy benefit management via...

Cigna Group is a global health company with two segments: Evernorth Health Services (pharmacy benefit management via Express Scripts, specialty pharmacy Accredo, and care services) and Cigna Healthcare (employer and individual health insurance, international health). Serves 185M+ customer relationships in 30+ markets; revenue from pharmacy fees, health premiums, and ASO fees.

Related stocks: CVS (CVS Health Corporation) · HUM (Humana Inc.) · CNC (Centene Corporation) · ELV (Elevance Health, Inc.) · UNH (UnitedHealth Group Incorporated)